Limits...
Factors related to use of prostate cancer screening: the Alberta Tomorrow Project.

Richardson H, Aronson KJ, James A, McGregor ES, Bryant H - Open Med (2007)

Bottom Line: Variables independently associated with recent PSA screening for prostate cancer in this population include older age (>/= 65 versus < 55 years: adjusted odds ratio [OR] 2.60; 95% confidence interval [CI] 1.77-3.83), higher income (>/= $80,000 versus < $20,000, OR 1.97; 95% CI 1.09-3.55), region of health care delivery, perception of health status (good versus excellent health status; OR 0.65, CI 0.43-0.96], increased number of chronic health conditions (OR 1.73, 95% CI 1.10-2.71), and history of colorectal cancer screening with fecal occult blood test (OR 2.21; 95% CI 1.73-2.83).An increasing proportion of men in Alberta are receiving a PSA test.A number of significant predictors of having a PSA test were identified, suggesting that factors other than having a clinical indication for prostate disease can influence decisions about PSA screening.

View Article: PubMed Central - HTML - PubMed

ABSTRACT

Background: Very few data are available on the determinants of PSA testing in Canada, and it is a matter of debate whether prostate-specific antigen (PSA) screening in asymptomatic men age 50 and older with no risk factors for prostate cancer is useful. If PSA screening is introduced into the periodic health examination, it will be important to know what factors influence its use.

Objectives: The purpose of this study is to determine the factors associated with PSA testing among asymptomatic men age 50 and older participating in the Tomorrow Project in Alberta.

Methods: The Tomorrow Project is a population-based cohort study with over 11,000 participants accrued in Alberta since February 2003. Information was collected on medical history, sociodemographic factors, health status and lifestyle characteristics. This analysis includes 2136 men 50 years of age and older. The independent association between various factors and recent PSA screening is estimated using logistic regression.

Results: Approximately 50% of of the study group had received one or more PSA tests in their lifetime. Of these, 58% were asymptomatic for prostate disease at the time of their most recent PSA test. Variables independently associated with recent PSA screening for prostate cancer in this population include older age (>/= 65 versus < 55 years: adjusted odds ratio [OR] 2.60; 95% confidence interval [CI] 1.77-3.83), higher income (>/= $80,000 versus < $20,000, OR 1.97; 95% CI 1.09-3.55), region of health care delivery, perception of health status (good versus excellent health status; OR 0.65, CI 0.43-0.96], increased number of chronic health conditions (OR 1.73, 95% CI 1.10-2.71), and history of colorectal cancer screening with fecal occult blood test (OR 2.21; 95% CI 1.73-2.83).

Conclusions: An increasing proportion of men in Alberta are receiving a PSA test. A number of significant predictors of having a PSA test were identified, suggesting that factors other than having a clinical indication for prostate disease can influence decisions about PSA screening.

No MeSH data available.


Related in: MedlinePlus

Sociodemographic characteristics, tobacco use and body mass index of selected cohort stratified by PSA testing status, n (%)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2801912&req=5

table2: Sociodemographic characteristics, tobacco use and body mass index of selected cohort stratified by PSA testing status, n (%)

Mentions: Table 2, Table 3, and Table 4 show the frequency distribution of sociodemographic and health-related characteristics stratified by men with different PSA testing status. There were no striking differences in the distribution of these factors between the PSA screening and PSA testing groups. However, men who were tested for PSA with a clinical indication tended to be older than men in the PSA screening group. Furthermore, the distribution of men attending the 5 main health care delivery regions differed between the two groups of men who had received PSA tests. The vast majority of men in the cohort received at least one DRE in their lifetime, and the time of the last DRE was highly correlated with the time of the last PSA test (Spearman r = 0.619, p < 0.001; data not shown). The most striking difference in the non-PSA tested group was the greater number of men who had never had a digital rectal examination compared to the other groups of men.


Factors related to use of prostate cancer screening: the Alberta Tomorrow Project.

Richardson H, Aronson KJ, James A, McGregor ES, Bryant H - Open Med (2007)

Sociodemographic characteristics, tobacco use and body mass index of selected cohort stratified by PSA testing status, n (%)
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2801912&req=5

table2: Sociodemographic characteristics, tobacco use and body mass index of selected cohort stratified by PSA testing status, n (%)
Mentions: Table 2, Table 3, and Table 4 show the frequency distribution of sociodemographic and health-related characteristics stratified by men with different PSA testing status. There were no striking differences in the distribution of these factors between the PSA screening and PSA testing groups. However, men who were tested for PSA with a clinical indication tended to be older than men in the PSA screening group. Furthermore, the distribution of men attending the 5 main health care delivery regions differed between the two groups of men who had received PSA tests. The vast majority of men in the cohort received at least one DRE in their lifetime, and the time of the last DRE was highly correlated with the time of the last PSA test (Spearman r = 0.619, p < 0.001; data not shown). The most striking difference in the non-PSA tested group was the greater number of men who had never had a digital rectal examination compared to the other groups of men.

Bottom Line: Variables independently associated with recent PSA screening for prostate cancer in this population include older age (>/= 65 versus < 55 years: adjusted odds ratio [OR] 2.60; 95% confidence interval [CI] 1.77-3.83), higher income (>/= $80,000 versus < $20,000, OR 1.97; 95% CI 1.09-3.55), region of health care delivery, perception of health status (good versus excellent health status; OR 0.65, CI 0.43-0.96], increased number of chronic health conditions (OR 1.73, 95% CI 1.10-2.71), and history of colorectal cancer screening with fecal occult blood test (OR 2.21; 95% CI 1.73-2.83).An increasing proportion of men in Alberta are receiving a PSA test.A number of significant predictors of having a PSA test were identified, suggesting that factors other than having a clinical indication for prostate disease can influence decisions about PSA screening.

View Article: PubMed Central - HTML - PubMed

ABSTRACT

Background: Very few data are available on the determinants of PSA testing in Canada, and it is a matter of debate whether prostate-specific antigen (PSA) screening in asymptomatic men age 50 and older with no risk factors for prostate cancer is useful. If PSA screening is introduced into the periodic health examination, it will be important to know what factors influence its use.

Objectives: The purpose of this study is to determine the factors associated with PSA testing among asymptomatic men age 50 and older participating in the Tomorrow Project in Alberta.

Methods: The Tomorrow Project is a population-based cohort study with over 11,000 participants accrued in Alberta since February 2003. Information was collected on medical history, sociodemographic factors, health status and lifestyle characteristics. This analysis includes 2136 men 50 years of age and older. The independent association between various factors and recent PSA screening is estimated using logistic regression.

Results: Approximately 50% of of the study group had received one or more PSA tests in their lifetime. Of these, 58% were asymptomatic for prostate disease at the time of their most recent PSA test. Variables independently associated with recent PSA screening for prostate cancer in this population include older age (>/= 65 versus < 55 years: adjusted odds ratio [OR] 2.60; 95% confidence interval [CI] 1.77-3.83), higher income (>/= $80,000 versus < $20,000, OR 1.97; 95% CI 1.09-3.55), region of health care delivery, perception of health status (good versus excellent health status; OR 0.65, CI 0.43-0.96], increased number of chronic health conditions (OR 1.73, 95% CI 1.10-2.71), and history of colorectal cancer screening with fecal occult blood test (OR 2.21; 95% CI 1.73-2.83).

Conclusions: An increasing proportion of men in Alberta are receiving a PSA test. A number of significant predictors of having a PSA test were identified, suggesting that factors other than having a clinical indication for prostate disease can influence decisions about PSA screening.

No MeSH data available.


Related in: MedlinePlus